http://orcid.org/0000-0002-7218-7762
Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Marko M. Folic, Zorana Djordjevic, Nevena Folic, Marija Zivkovic Radojevic & Slobodan M. Jankovic. (2021) Epidemiology and risk factors for healthcare-associated infections caused by Pseudomonas aeruginosa. Journal of Chemotherapy 33:5, pages 294-301.
Read now
Read now
Qi Xia, Ruihong Zhao, Haotang Ren, Hong Fang & Yina Wang. (2019) Epidemiological investigation of non-fermentative bacterial infection in cirrhotic patients. Expert Review of Gastroenterology & Hepatology 13:8, pages 815-820.
Read now
Read now
Sebastiano Leone, Marco Cascella, Ilaria Pezone & Marco Fiore. (2019) New antibiotics for the treatment of serious infections in intensive care unit patients. Current Medical Research and Opinion 35:8, pages 1331-1334.
Read now
Read now
Daniele Roberto Giacobbe, Silvia Corcione, Antonio Salsano, Filippo Del Puente, Simone Mornese Pinna, Francesco Giuseppe De Rosa, Malgorzata Mikulska, Francesco Santini & Claudio Viscoli. (2019) Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opinion on Pharmacotherapy 20:6, pages 751-772.
Read now
Read now
Daniele Roberto Giacobbe, Malgorzata Mikulska & Claudio Viscoli. (2018) Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Review of Clinical Pharmacology 11:12, pages 1219-1236.
Read now
Read now
Alberto Enrico Maraolo, Ivan Gentile, Biagio Pinchera, Salvatore Nappa & Guglielmo Borgia. (2018) Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. Expert Opinion on Pharmacotherapy 19:12, pages 1317-1325.
Read now
Read now
Alberto Enrico Maraolo, Marco Cascella, Silvia Corcione, Arturo Cuomo, Salvatore Nappa, Guglielmo Borgia, Francesco Giuseppe De Rosa & Ivan Gentile. (2018) Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’. Expert Review of Anti-infective Therapy 16:5, pages 369-371.
Read now
Read now
Articles from other publishers (38)
Alberto Enrico Maraolo. (2023) Editorial for the Special Issue: “The Issue of Multidrug-Resistant Pathogens in Nosocomial Infections”. Antibiotics 12:12, pages 1683.
Crossref
Crossref
Zeina A. Kanafani, Ahmad Sleiman, Jim Abi Frem, George Doumat, Amal Gharamti, Bassam El Hafi, Michel Doumith, Majed F. AlGhoribi, Souha S. Kanj, George F. Araj, Ghassan M. Matar & Antoine G. Abou Fayad. (2023) Molecular characterization and differential effects of levofloxacin and ciprofloxacin on the potential for developing quinolone resistance among clinical Pseudomonas aeruginosa isolates. Frontiers in Microbiology 14.
Crossref
Crossref
Prity Rani Deshwal, Muskan Aggarwal, Nalla Surender Reddy, Raisa Fathima & Pramil Tiwari. (2023) Association of β-lactam antimicrobial's exposure with carbapenem-resistant Pseudomonas aeruginosa infection: a cumulative meta-analysis. Global Health Journal.
Crossref
Crossref
Jim Abi Frem, George Doumat, Jamil Kazma, Amal Gharamti, Souha S. Kanj, Antoine G. Abou Fayad, Ghassan M. Matar & Zeina A. Kanafani. (2023) Clinical predictors of mortality in patients with pseudomonas aeruginosa infection. PLOS ONE 18:4, pages e0282276.
Crossref
Crossref
Jacopo Garlasco, Iva Beqiraj, Cesare Bolla, Elisabeth Maria Irene Marino, Cristian Zanelli, Corrado Gualco, Andrea Rocchetti & Maria Michela Gianino. (2023) Impact of septic episodes caused by Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa in a tertiary hospital: clinical and economic considerations in years 2018–2020. Journal of Infection and Public Health 16:4, pages 475-482.
Crossref
Crossref
Taghreed A. Hafiz, Eman A. Bin Essa, Sarah R. Alharbi, Ahmed S. Alyami, Zeina S. Alkudmani, Murad A. Mubaraki, Norah A. Alturki & Fawzia Alotaibi. (2023) Epidemiological, Microbiological, and Clinical Characteristics of Multi-Resistant Pseudomonas aeruginosa Isolates in King Fahad Medical City, Riyadh, Saudi Arabia. Tropical Medicine and Infectious Disease 8:4, pages 205.
Crossref
Crossref
Thitiporn Ditsawanon, Narumon Phaonakrob & Sittiruk Roytrakul. (2023) Mechanisms of Antimicrobial Peptides from Bagasse against Human Pathogenic Bacteria. Antibiotics 12:3, pages 448.
Crossref
Crossref
Xuan Nie, Fan Gao, Wei You, Guang Chen, Qi Shao, Long-Hai Wang, Wei-Qiang Huang, Lei Xia, Ze Zhang, Chun-Yan Hong & Ye-Zi You. (2022) Caging pyrophosphate structure blocks the cell wall synthesis to kill bacteria without detectable resistance. Chemical Engineering Journal 450, pages 138373.
Crossref
Crossref
Andreas F. Wendel, Monika Malecki, Frauke Mattner, Kyriaki Xanthopoulou, Julia Wille, Harald Seifert & Paul G. Higgins. (2022)
Genomic-based transmission analysis of carbapenem-resistant
Pseudomonas aeruginosa
at a tertiary care centre in Cologne (Germany) from 2015 to 2020
. JAC-Antimicrobial Resistance 4:3.
Crossref
Crossref
Young Ah Kim, Junglim Kim, Young Jun Son & Sang Sun Lee. (2022)
Evaluation of the Reliability of Automated Colistin Susceptibility Assays of
Pseudomonas aeruginosa
. Journal of Laboratory Medicine and Quality Assurance 44:1, pages 36-39.
Crossref
Crossref
Cajsa M. Isgren, Nicola J. Williams, Owen D. Fletcher, Dorina Timofte, Richard J. Newton, Thomas W. Maddox, Peter D. Clegg & Gina L. Pinchbeck. (2021) Antimicrobial resistance in clinical bacterial isolates from horses in the UK. Equine Veterinary Journal 54:2, pages 390-414.
Crossref
Crossref
Ashish Kothari, Neeraj Jain, Shyam Kishor Kumar, Ankur Kumar, Karanvir Kaushal, Satinder Kaur, Atul Pandey, Amit Gaurav & Balram Ji Omar. (2022) Potential Synergistic Antibiotic Combinations against Fluoroquinolone-Resistant Pseudomonas aeruginosa. Pharmaceuticals 15:2, pages 243.
Crossref
Crossref
Ahmed R. Rezk, Somaia Abdelhammed Bawady & Nashwa Naguib Omar. (2021) Incidence of emerging multidrug-resistant organisms and its impact on the outcome in the pediatric intensive care. Egyptian Pediatric Association Gazette 69:1.
Crossref
Crossref
Andreu Coello Pelegrin, Mattia Palmieri, Caroline Mirande, Antonio Oliver, Pieter Moons, Herman Goossens & Alex van Belkum. (2021)
Pseudomonas aeruginosa
: a clinical and genomics update
. FEMS Microbiology Reviews 45:6.
Crossref
Crossref
Depeng Zhu, Fangyi Chen, Yan-Chao Chen, Hui Peng & Ke-Jian Wang. (2021) The Long-Term Effect of a Nine Amino-Acid Antimicrobial Peptide AS-hepc3(48-56) Against Pseudomonas aeruginosa With No Detectable Resistance. Frontiers in Cellular and Infection Microbiology 11.
Crossref
Crossref
Nabamita Basu & Rina Ghosh. (2021) Recent chemical syntheses of bacteria related oligosaccharides using modern expeditious approaches. Carbohydrate Research 507, pages 108295.
Crossref
Crossref
Olga Lomovskaya, Debora Rubio-Aparicio, Kirk Nelson, Dongxu Sun, Ruslan Tsivkovski, Mariana Castanheira, Jill Lindley, Jeffery Loutit & Michael Dudley. (2021)
In Vitro
Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa
. Antimicrobial Agents and Chemotherapy 65:6.
Crossref
Crossref
Lucas Borges Pereira, Maria Olívia Barboza Zanetti, Larissa Pombeiro Sponchiado, João Paulo Vilela Rodrigues, Marília Silveira de Almeida Campos, Fabiana Rossi Varallo & Leonardo Régis Leira Pereira. (2021) Antibiotic use in Brazilian hospitals in the 21st century: a systematic review. Revista da Sociedade Brasileira de Medicina Tropical 54.
Crossref
Crossref
Milo Gatti, Maddalena Giannella, Emanuel Raschi, Pierluigi Viale & Fabrizio De Ponti. (2021) Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. Journal of Antimicrobial Chemotherapy 76:1, pages 199-205.
Crossref
Crossref
Sebastian Fischer, Sarah Dethlefsen, Jens Klockgether & Burkhard Tümmler. (2020) Phenotypic and Genomic Comparison of the Two Most Common ExoU-Positive Pseudomonas aeruginosa Clones, PA14 and ST235. mSystems 5:6.
Crossref
Crossref
Brittany E Kula, Darren Hudson & Wendy I Sligl. (2020)
Pseudomonas aeruginosa
infection in intensive care: Epidemiology, outcomes, and antimicrobial susceptibilities
. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 5:3, pages 130-138.
Crossref
Crossref
Chuen-Fu Lin, Meng-Yi Lin, Chao-Nan Lin, Ming-Tang Chiou, Jia-Wen Chen, Kai-Chieh Yang & Ming-Cheng Wu. (2020) Potential probiotic of Lactobacillus strains isolated from the intestinal tracts of pigs and feces of dogs with antibacterial activity against multidrug-resistant pathogenic bacteria. Archives of Microbiology 202:7, pages 1849-1860.
Crossref
Crossref
Silke Peter, Mattia Bosio, Caspar Gross, Daniela Bezdan, Javier Gutierrez, Philipp Oberhettinger, Jan Liese, Wichard Vogel, Daniela Dörfel, Lennard Berger, Matthias Marschal, Matthias Willmann, Ivo Gut, Marta Gut, Ingo Autenrieth & Stephan Ossowski. (2020) Tracking of Antibiotic Resistance Transfer and Rapid Plasmid Evolution in a Hospital Setting by Nanopore Sequencing. mSphere 5:4.
Crossref
Crossref
Luzelena Caro, David P Nicolau, Jan J De Waele, Joseph L Kuti, Kajal B Larson, Elaine Gadzicki, Brian Yu, Zhen Zeng, Adedayo Adedoyin & Elizabeth G Rhee. (2020) Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy 75:6, pages 1546-1553.
Crossref
Crossref
Irene Galani, Vassiliki Papoutsaki, Irene Karantani, Ilias Karaiskos, Lamprini Galani, Panagiota Adamou, Ioannis Deliolanis, Antigoni Kodonaki, Eleni Papadogeorgaki, Margarita Markopoulou, Sofia Maraki, Maria Damala, Eleni Prifti, Eleni Vagiakou, Efthimia Petinaki, Kimon Fountoulis, Sophia Tsiplakou, Helen Kirikou, Maria Souli, Anastasia Antoniadou & Helen Giamarellou. (2020) In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Journal of Antimicrobial Chemotherapy.
Crossref
Crossref
Lingman Ma, Xinyue Ye, Pengbo Sun, Pengfei Xu, Liping Wang, Zixiang Liu, Xiaowei Huang, Zhaoshi Bai & Changlin Zhou. (2020) Antimicrobial and antibiofilm activity of the EeCentrocin 1 derived peptide EC1-17KV via membrane disruption. EBioMedicine 55, pages 102775.
Crossref
Crossref
A. R. Buonomo, A. E. Maraolo, R. Scotto, M. Foggia, E. Zappulo, P. Congera, S. Parente & I. Gentile. (2020) Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience. Infection 48:2, pages 303-307.
Crossref
Crossref
Alberto Enrico Maraolo, Maria Mazzitelli, Enrico Maria Trecarichi, Antonio Riccardo Buonomo, Carlo Torti & Ivan Gentile. (2020) Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. International Journal of Antimicrobial Agents 55:3, pages 105891.
Crossref
Crossref
Silvia Corcione, Tommaso Lupia, Alberto Enrico Maraolo, Simone Mornese Pinna, Ivan Gentile & Francesco G. De Rosa. (2019) Carbapenem-sparing strategy. Current Opinion in Infectious Diseases 32:6, pages 663-673.
Crossref
Crossref
Milka Malešević, Flaviana Di Lorenzo, Brankica Filipić, Nemanja Stanisavljević, Katarina Novović, Lidija Senerovic, Natalija Polović, Antonio Molinaro, Milan Kojić & Branko Jovčić. (2019) Pseudomonas aeruginosa quorum sensing inhibition by clinical isolate Delftia tsuruhatensis 11304: involvement of N-octadecanoylhomoserine lactones. Scientific Reports 9:1.
Crossref
Crossref
Benjamin VialaFatma Zohra ZaidiMathilda BastideYann DumontVincent Le MoingHélène Jean-PierreSylvain Godreuil. (2019)
Assessment of the
In Vitro
Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and
Pseudomonas aeruginosa
Clinical Isolates at Montpellier University Hospital, France
. Microbial Drug Resistance 25:9, pages 1325-1329.
Crossref
Crossref
Juan P. Horcajada, Milagro Montero, Antonio Oliver, Luisa Sorlí, Sònia Luque, Silvia Gómez-Zorrilla, Natividad Benito & Santiago Grau. (2019) Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews 32:4.
Crossref
Crossref
Tomefa E. Asempa, David P. Nicolau & Joseph L. Kuti. (2019)
Carbapenem-Nonsusceptible
Pseudomonas aeruginosa
Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents
. Journal of Clinical Microbiology 57:8.
Crossref
Crossref
Lindsay M. Avery, Christina A. Sutherland & David P. Nicolau. (2019) Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa. Journal of Medical Microbiology 68:6, pages 893-897.
Crossref
Crossref
Burkhard Tümmler. (2019) Emerging therapies against infections with Pseudomonas aeruginosa. F1000Research 8, pages 1371.
Crossref
Crossref
Meenakshi M. Rana, Paolo Grossi & Shirish Huprikar. 2019. Infectious Diseases in Solid-Organ Transplant Recipients. Infectious Diseases in Solid-Organ Transplant Recipients
145
163
.
James A. Karlowsky, Sibylle H. Lob, Katherine Young, Mary R. Motyl & Daniel F. Sahm. (2018) Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015–2016. Journal of Global Antimicrobial Resistance 15, pages 140-147.
Crossref
Crossref
Xuan Nie, Fan Gao, Wei You, Guang Chen, Qi Shao, Long-Hai Wang, Weiqiang Huang, Lei Xia, Ze Zhang, Chun-Yan Hong & Yezi You. (2022) Caging Udp Kills Bacteria Without Detectable Resistance. SSRN Electronic Journal.
Crossref
Crossref